0001104659-24-077834.txt : 20240703 0001104659-24-077834.hdr.sgml : 20240703 20240703171655 ACCESSION NUMBER: 0001104659-24-077834 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231117 FILED AS OF DATE: 20240703 DATE AS OF CHANGE: 20240703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Maccecchini Maria-Luisa CENTRAL INDEX KEY: 0001315018 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39202 FILM NUMBER: 241100933 MAIL ADDRESS: STREET 1: 1223 FOXGLOVE LANE CITY: WEST CHESTER STATE: PA ZIP: 19380 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Annovis Bio, Inc. CENTRAL INDEX KEY: 0001477845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262540421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 LINDENWOOD DRIVE, SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-875-3192 MAIL ADDRESS: STREET 1: 101 LINDENWOOD DRIVE, SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: QR Pharma, Inc. DATE OF NAME CHANGE: 20091202 4 1 tm2417696-3_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-11-17 0 0001477845 Annovis Bio, Inc. ANVS 0001315018 Maccecchini Maria-Luisa C/O ANNOVIS BIO, INC. 101 LINDENWOOD DR, SUITE 225 MALVERN PA 19355 1 1 1 0 President and CEO 0 Common Stock 2024-03-28 4 G 0 10000 0 D 1088459 D Common Stock 2024-03-31 4 G 0 10000 0 D 1078459 D Common Stock 2024-03-31 4 G 0 10000 0 D 1068459 D Stock Option (right to buy) 6.07 2023-11-17 4 A 0 252000 0 A 2033-11-17 Common Stock 252000 252000 D Stock Option (right to buy) 6.07 2023-11-17 4 A 0 108800 0 A 2033-11-17 Common Stock 108800 108800 D Represents charitable gifts donated by the reporting person. No proceeds were received by the reporting person. On June 12, 2024, stockholders of Annovis Bio, Inc. approved an amendment to the 2019 Equity Incentive Plan to increase the number of shares issuable thereunder from 2,000,000 to 3,000,000. 50% of the stock option grant listed was contingent upon the approval of such amendment and would have been forfeited if the amendment had not been approved. Stock option will vest in eight consecutive quarterly installments of 31,500 shares each on the 17th day of February, May, August and November of each year, continuing through November 17, 2025. The stock option was granted in lieu of cash payment for 2023 fiscal year bonus. 100% of the stock option grant listed was also contingent upon the aforementioned amendment to the 2019 Equity Incentive Plan to increase the number of issuable shares from 2,000,000 to 3,000,000. It would have been forfeited if the amendment had not been approved. The stock option shall vest immediately. /s/ Maria Maccecchini 2024-07-03